It Was All a Dream
Editor's Note: Patient Worthy is honored to share Michelle Patidar's patient story, provided to us by our friends at Elephants & Tea. To see the article in its original format,…
Continue Reading
It Was All a Dream
Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment
Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard R-CHOP regimen for newly diagnosed…
Continue Reading
Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment
Sugar-Coated Deception: Discovery of Aggressive Lymphoma Subtype Opens Door to Personalized Cancer Treatment
Researchers at the University of Southampton have uncovered a hidden culprit in blood cancer, a unique sugar molecule that disguises aggressive lymphoma cells and renders them resistant to conventional treatments.…
Continue Reading
Sugar-Coated Deception: Discovery of Aggressive Lymphoma Subtype Opens Door to Personalized Cancer Treatment
Mann-type DLBCL: Sugar Signature Reveals High-Risk Lymphoma and New Therapeutic Avenues
University of Southampton researchers have identified a distinct subtype of diffuse large B‑cell lymphoma (DLBCL), termed “Mann-type DLBCL,” marked by a unique mannose sugar on the B‑cell receptor that fuels…
Continue Reading
Mann-type DLBCL: Sugar Signature Reveals High-Risk Lymphoma and New Therapeutic Avenues
NHS Fast-Tracks Glofitamab, Expanding Curative Options for Aggressive Lymphoma
Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from the National Institute for Health…
Continue Reading
NHS Fast-Tracks Glofitamab, Expanding Curative Options for Aggressive Lymphoma
Second Chance at Life: Glofitamab Accelerates Hope for Aggressive Blood Cancer Patients on NHS
The NHS has dramatically expanded access to a life-saving cancer therapy, according to NHS England, offering approximately 300 blood cancer patients in England annually a genuine chance at complete remission.…
Continue Reading
Second Chance at Life: Glofitamab Accelerates Hope for Aggressive Blood Cancer Patients on NHS
Europe Approves Columvi for Relapsed or Refractory DLBCL
Having a rare or uncommon condition can be undoubtedly overwhelming. The diagnosis comes with associated mental health, financial, physical, and social burdens that can weigh heavy on your mind. But…
Continue Reading
Europe Approves Columvi for Relapsed or Refractory DLBCL
source: shutterstock.com
A New Treatment for Diffuse Large B-Cell Lymphoma Could be on its Way to EU Approval
According to a story from Market Screener, the drug company AbbVie recently announced that its investigational therapy epcoritamab has received a positive opinion from the European Union's Committee for Medicinal…
Continue Reading
A New Treatment for Diffuse Large B-Cell Lymphoma Could be on its Way to EU Approval
webandi / Pixabay
Enrollment Ceases for Phase 2 Study for DLBCL After 7 People Die
According to a July 11 article from Maaisha Osman, commercial-stage biotechnology company ADC Therapeutics has voluntarily halted enrollment for the Phase 2 LOTIS-9 study evaluating Zynlonta (loncastuximab tesirine-lpyl) and…
Continue Reading
Enrollment Ceases for Phase 2 Study for DLBCL After 7 People Die
https://pixabay.com/en/united-states-capitol-politics-1675539/
Rep. Jamie Raskin Shares Update on DLBCL, Says He is in Remission
In December 2022, Representative Jamie Raskin (D-MD) shared with the public that he had been diagnosed with diffuse large B-cell lymphoma (DLBCL). Although being diagnosed with cancer can be frightening,…
Continue Reading
Rep. Jamie Raskin Shares Update on DLBCL, Says He is in Remission
source: pixabay.com
Shared Treatment Decision-Making for DLBCL Patients
Previous research presents strong evidence favoring shared decision-making after a medical diagnosis. One major improvement has been designing treatment plans that include a good deal of the patient’s goals and…
Continue Reading
Shared Treatment Decision-Making for DLBCL Patients
Study: Diffuse Large B-Cell Lymphoma Patients May Benefit from Involvement in Decision Making
Due to varied periods of decline among patients, previous research indicates that it is difficult to develop treatment options for patients who have relapsed DLBCL. This holds true especially when…
Continue Reading
Study: Diffuse Large B-Cell Lymphoma Patients May Benefit from Involvement in Decision Making
source: unsplash.com
Diffuse Large B-Cell Lymphoma: Combination Treatment Superior to Systemic Therapy in Retrospective Study
According to a story from Cancer Network, the results of a recent retrospective study have found that a two-part combination treatment for diffuse large B-cell lymphoma (DLBCL), a rare cancer,…
Continue Reading
Diffuse Large B-Cell Lymphoma: Combination Treatment Superior to Systemic Therapy in Retrospective Study
source: pixabay.com
Second Line Therapies for Diffuse Large B-Cell Lymphoma
According to a case-based roundtable meeting for Targeted Oncology, Matthew A. Lunning, DO, talked about second-line therapies for diffuse large B-cell lymphoma and the results of a study called L-MIND.…
Continue Reading
Second Line Therapies for Diffuse Large B-Cell Lymphoma
source: pixabay.com
Mark Hoppus is Back to Music After His Diffuse Large B-Cell Lymphoma Battle
Mark Hoppus has been working in the music industry for three decades; his band, Blink 182, was formed back in 1992. He has a strong love for writing, performing, and…
Continue Reading
Mark Hoppus is Back to Music After His Diffuse Large B-Cell Lymphoma Battle
pixabay.com
Certain Subtypes of DLBCL Respond Better to Ibrutinib Plus R-CHOP
According to a recent article from Hematology Advisor, a study shows patients diagnosed with particular subtypes of diffuse large B-cell lymphoma (DLBCL) respond better to ibrutinib with R-CHOP compared to…
Continue Reading
Certain Subtypes of DLBCL Respond Better to Ibrutinib Plus R-CHOP
source: pixabay.com
Survival for Young Patients with Diffuse Large B-Cell Lymphoma Improved by Ibrutinib
According to a recent article, new evidence shows adding ibrutinib to a patient’s chemotherapy regimen may improve the longevity of younger patients with diffuse large B-cell lymphoma (DLBCL). Diffuse Large…
Continue Reading
Survival for Young Patients with Diffuse Large B-Cell Lymphoma Improved by Ibrutinib
First Patient Dosed in MVP-S, KEYTRUDA Study for DLBCL
According to a news release from immuno-oncology company IMV Inc., the first patient has been dosed in the Phase 2b VITALIZE clinical trial. During the trial, researchers are evaluating a…
Continue Reading
First Patient Dosed in MVP-S, KEYTRUDA Study for DLBCL
source: pixabay.com
C-CAR039 Earns RMAT, Fast Track Designations for DLBCL
According to the Cancer Network, a CAR T-cell therapy called C-CAR039 recently earned both Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration.…
Continue Reading
C-CAR039 Earns RMAT, Fast Track Designations for DLBCL
source: shutterstock.com
Nana-val for DLBCL Earns Orphan Drug Designation
According to Healio, the FDA recently granted Orphan Drug designation to nanatinostat and valganciclovir ("Nana-val") for the treatment of patients with Epstein Barr virus+ diffuse large B-cell lymphoma (DLBCL). In…
Continue Reading
Nana-val for DLBCL Earns Orphan Drug Designation
source: pixabay.com
DPX Delivery Platform Could Improve Care For Many Rare Cancers
IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…
Continue Reading
DPX Delivery Platform Could Improve Care For Many Rare Cancers
My Genetically Altered Life: How CAR-T Transformed My Life with Diffuse Large B-Cell Lymphoma
Written by Robyn Stacy-Humphries Wolverine, Spiderman, Wonder Woman, and Deadpool - superheroes most of us love. Why? They have superpowers and escape death by some type of genetic alteration. Humans…
Continue Reading
My Genetically Altered Life: How CAR-T Transformed My Life with Diffuse Large B-Cell Lymphoma
source: pixabay.com
New Therapy Shown to Improve Survival in Diffuse Large B-Cell Lymphoma
Results from a recent Phase 3 trial for diffuse large B-cell lymphoma (DLBCL) have just been released! This trial was called POLARIX and the results demonstrated that polatuzumab vedotin-based treatment…
Continue Reading
New Therapy Shown to Improve Survival in Diffuse Large B-Cell Lymphoma
source: pixabay.com
Diffuse Large B-Cell Lymphoma Research Aims to Overcome Short Duration of Response
Gilles Salles works at the Memorial Sloan Kettering Cancer Center as the Lymphoma Service Chief. She recently sat down to discuss the necessity of new treatments for diffuse large B-Cell…
Continue Reading
Diffuse Large B-Cell Lymphoma Research Aims to Overcome Short Duration of Response
biker_becca / Pixabay
Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
In the Phase 2 LOTIS-2 clinical trial, researchers evaluated the safety, efficacy, and tolerability of Loncastuximab tesirine for patients with aggressive diffuse large B-cell lymphoma (DLBCL). While there are treatment…
Continue Reading
Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
